ClinicalTrials.Veeva

Menu
M

Monash Health | Neurology Department

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Tislelizumab
Zanubrutinib
BGB-3111
Pembrolizumab
BGB-11417
Platinum
Nivolumab
Palbociclib
Lenalidomide
ARO-APOC3

Parent organization

This site is a part of Monash Health

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

87 of 164 total trials

A Feasibility Study of the Millipede Transcatheter Annuloplasty Ring System in Patients With Functional Mitral Regurgitation

To evaluate the feasibility and safety of the Millipede Transcatheter Annuloplasty Ring System in subjects with functional mitral regurgitation

Active, not recruiting
Mitral Valve Disease
Cardiovascular Diseases
Device: Millipede Transcatheter Annuloplasty Ring System (Millipede System)

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-...

Enrolling
Advanced Solid Tumor
Drug: BG-C137

This is a first-in-human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinet...

Enrolling
Advanced Pancreatic Ductal Adenocarcinoma
Advanced Non-squamous Non-small-cell Lung Cancer
Drug: Cetuximab
Drug: BGB-53038

This is a Phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, and DLTs to establish the maximum tolerated dose (M...

Enrolling
Locally Advanced Unresectable or Metastatic Solid Tumors
Biological: IBI354

Study consists of two parts, a part 1 dose escalation and a part 2 cohort expansion in combination with dexamethasone and carfilzomib intravenously a...

Enrolling
Relapsed/Refractory Multiple Myeloma
Drug: Carfilzomib
Drug: Dexamethasone

This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) cause...

Not yet enrolling
Sickle Cell Disease
Drug: Placebo
Drug: Etavopivat

he purpose of the study is to evaluate the efficacy, safety, and tolerability BGB-3111 plus obinutuzumab versus obinutuzumab alone in participants wi...

Active, not recruiting
Relapsed/Refractory Follicular Non-Hodgkin Lymphoma
Drug: Zanubrutinib
Drug: Obinutuzumab

The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission. Ozanimod...

Enrolling
Colitis, Ulcerative
Drug: Ozanimod

This is a Phase 1b/2 study to investigate the efficacy and safety of LBL-007 plus Tislelizumab when administered in combination with bevacizumab plus...

Enrolling
Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
Drug: 5-Fluorouracil
Drug: Tislelizumab

The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse....

Active, not recruiting
Cytochrome P-450
Antineoplastic Agents, Hormonal
Drug: Placebo for Abemaciclib
Drug: Abemaciclib

This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK112...

Enrolling
Neoplasms Malignant
Drug: AK112

This is a first-in-human (FIH), Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokineti...

Active, not recruiting
Advanced or Metastatic Solid Tumors
Biological: AK119
Biological: AK104

The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combin...

Enrolling
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasm
Drug: BGB-11417
Drug: Azacitidine

This study is testing the safety and tolerability of BGB-21447 monotherapy in participants with relapsed or refractory (R/R) non-Hodgkin lymphoma (NH...

Enrolling
Refractory Small Lymphocytic Lymphoma
Transformed Non-Hodgkin Lymphoma
Drug: BGB-21447

This is a First in Human (FIH) Phase 1, multicenter, open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharm...

Enrolling
Advanced Solid Tumors
Drug: Tislelizumab
Drug: BGB-30813

CLN-619-001 is a Phase 1, open-label, multi-center study of CLN-619 alone and in combination with pembrolizumab in patients with advanced solid tumor...

Enrolling
Advanced Solid Tumor
Drug: CLN-619
Drug: Pembrolizumab

The purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab) taken alone or together with standard chemotherapy for the...

Active, not recruiting
Neoplasms
Drug: Cetuximab
Drug: Oxaliplatin

The goal of this study is to test the effectiveness, safety, and tolerability of the combination of broadly neutralizing antibodies (bNAbs) (teropavi...

Active, not recruiting
HIV Infections
Drug: Lenacapavir Tablet
Drug: Zinlirvimab
Locations recently updated

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis...

Active, not recruiting
Ulcerative Colitis
Drug: Guselkumab
Drug: Placebo

The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in...

Active, not recruiting
Colitis, Ulcerative
Drug: Guselkumab Dose 2
Other: Placebo

Trial sponsors

BeiGene logo
Bristol-Myers Squibb (BMS) logo
Gilead Sciences logo
Pfizer logo
W
AbbVie logo
Arrowhead Pharmaceuticals logo
Boston Scientific logo
Mirati Therapeutics logo
Roche logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems